



Cytokinetics Announces Presentations Relating to Clinical Trial Data on CK-1827452 and its Cardiac Myosin Activator Program at the 2006 Annual American Heart Association Scientific Sessions Meeting

November 6, 2006 5:00 AM EST

South San Francisco, CA, November 6, 2006 - Cytokinetics, Incorporated (Nasdaq: CYTK) announced today that clinical trial data regarding CK-1827452, and non-clinical data arising from Cytokinetics' cardiovascular program directed towards cardiac myosin activators, will be presented at the 2006 Annual American Heart Association (AHA) Scientific Sessions Meeting to be held from November 12-15, 2006 in Chicago, Illinois.

Oral Presentations at the 2006 Annual American Heart Association Scientific Sessions

Abstract #2169: The Selective Cardiac Myosin Activator, CK-1827452, a Calcium-Independent Inotrope, Increases Left Ventricular Systolic Function by Increasing Ejection Time Rather than the Velocity of Contraction. (Oral Presentation on Monday, November 13, 2006, 9:00 a.m. – 12:15 p.m. CT at McCormick Place, Room S102bcd. The presentation will be made by John R. Teerlink, MD, FACC, FAHA, FESC, University of California, San Francisco and Director of the Heart Failure Clinic, Veterans Affairs Medical Center.)

Abstract #1439: Activating Cardiac Myosin, a Novel Inotropic Mechanism to Improve Cardiac Function in Conscious Dogs with Congestive Heart Failure. (Oral Presentation on Wednesday, November 15, 2006, 9:00 a.m. – 12:00 p.m. CT at McCormick Place, Room E450a. The presentation will be made by Fady Malik, MD, PhD, FACC, Cytokinetics, Inc.)

Abstract #1440: The Cardiac Myosin Activator CK-1316719 Increases Myofibril ATPase Activity and Myocyte Contractility in a Rat Model of Heart Failure. (Oral Presentation on Wednesday, November 15, 2006, 9:00 a.m. – 12:00 p.m. CT at McCormick Place, Room E450a. The presentation will be made by Robert L. Anderson, Cytokinetics, Inc.)

Development Status of CK-1827452

A Phase I, first-in-humans clinical trial designed to evaluate a six-hour intravenous infusion of CK-1827452, a novel, small-molecule, direct activator of cardiac myosin, was recently completed in healthy volunteers. This clinical trial was conducted to investigate the safety, tolerability, pharmacokinetics and pharmacodynamic profile of a six-hour infusion of CK-1827452 in healthy volunteers. In this Phase I clinical trial, the maximum tolerated dose (MTD) was determined to be 0.5 mg/kg/hr for the six-hour infusion in healthy volunteers. At this dose, the six-hour infusion of CK-1827452 produced a mean increase in left ventricular ejection fraction of 6.8 absolute percentage points as compared to placebo (p